Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.

Support Care Cancer 2017 11 20;25(11):3537-3544. Epub 2017 Jun 20.

Mayo Clinic Cancer Center, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

Purpose: Clinical practice guidelines on chemotherapy-induced peripheral neuropathy (CIPN) use the NCI Common Terminology Criteria for Adverse Events (CTCAE), while recent clinical trials employ a potentially superior measure, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale (QLQ-CIPN20), a patient-reported outcome (PRO). Practitioners and researchers lack guidance, regarding how QLQ-CIPN20 results relate to the traditional CTCAE during the serial assessment of patients undergoing chemotherapy.

Methods: Two large CIPN clinical trial datasets (538 patients) pairing QLQ-CIPN20 and CTCAE outcomes were analyzed using a multivariable linear mixed model with QLQ-CIPN20 score as the outcome variable, CTCAE grade as the main effect, and patient as random effect (accounting for internal correlation of serial measures).

Results: The association between QLQ-CIPN20 scores and CTCAE grades was strong (p < 0.0001), whereby patients with higher CTCAE grade had worse QLQ-CIPN20 scores. Some variation of QLQ-CIPN20 scores was observed based on drug, treatment, and cycle. While there was a marked difference in the mean QLQ-CIPN20 scores between CTCAE grades, the ranges of QLQ-CIPN20 scores within each CTCAE grade were large, leading to large overlap in CIPN20 scores across CTCAE grades.

Conclusions: A strong positive association of QLQ-CIPN20 scores and CTCAE grade provides evidence of convergent validity as well as practical guidance, as to how to quantitatively interpret QLQ-CIPN20 scores at the study level in terms of the traditional CTCAE. The present results also highlight an important clinical caveat, specifically, that conversion of a specific QLQ-CIPN20 score to a specific CTCAE score may not be reliable at the level of an individual patient.

Download full-text PDF

Source
http://link.springer.com/10.1007/s00520-017-3780-y
Publisher Site
http://dx.doi.org/10.1007/s00520-017-3780-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693734PMC
November 2017
68 Reads

Publication Analysis

Top Keywords

clinical trials
8
peripheral neuropathy
8
qlq-cipn20
6
ctcae
6
scale qlq-cipn20
4
outcome pro
4
patient-reported outcome
4
qlq-cipn20 patient-reported
4
variable ctcae
4
practitioners researchers
4
lack guidance
4
guidance qlq-cipn20
4
researchers lack
4
outcome variable
4
twenty-item scale
4
pro practitioners
4
questionnaire-cipn twenty-item
4
patient random
4
organization treatment
4
outcomes analyzed
4

Similar Publications